Preferences help
enabled [disable] Abstract
Number of results
2018 | 105 | 157-167
Article title

Progressive forms of multiple sclerosis: disease-modifying therapy review

Title variants
Languages of publication
Multiple sclerosis (MS) is a demyelinating, inflammatory, autoimmune disease of the central nervous system which affects most commonly young adults. It has wide spectrum of clinical and radiological presentations with relapses or steady progression. Recent years have brought new reports on the pathogenesis of MS. This systematized the current MS classification and created new parameters describing the course of the disease, such as activity and progression. Attention has been paid to the need for new drugs that focus on the treatment of progressive MS. Until now, the primary and secondary progressive MS have been somewhat forgotten, and most of modifying-disease drugs have been registered in the treatment of relapsing-remitting subtype. In recent years, not only new drug has been registered for the treatment of progressive MS (ocrelizumab) and another one is planned to be approved soon (siponimod), but also indications of old medicines (interferon-beta1b, cladribine, mitoxantrone, cyclophosphamide, azathioprine) have been extended. Despite intensive development, there is still a great need to seek new drugs that will stop the progression of disability in MS patients.
Physical description
  • Chair and Department of Neurology, Medical University of Lublin, Lublin, Poland
  • Chair and Department of Neurology, Medical University of Lublin, Lublin, Poland
  • Chair and Department of Neurology, Medical University of Lublin, Lublin, Poland
  • Chair and Department of Neurology, Medical University of Lublin, Lublin, Poland
  • Chair and Department of Neurology, Medical University of Lublin, Lublin, Poland
  • Chair and Department of Neurology, Medical University of Lublin, Lublin, Poland
  • [1] Rosati G. The prevalence of multiple sclerosis in the world: an update. Neurological Sciences: Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 22 (2), 2001, s. 117–139.
  • [2] Rejdak K, Jackson S, Giovannoni G. Multiple sclerosis: a practical overview for clinicians. British Medical Bulletin. 2010; 95:79-104.
  • [3] Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33 (11), 1983, s. 1444–1452.
  • [4] Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 1996; 46:907–911.
  • [5] Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ et al. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology. 2014; 83(3): 278-286.
  • [6] Miller D, Barkhof F, Montalban X, Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. The Lancet Neurology. 2005; 4: 281–288.
  • [7] Okuda DT, Mowry EM, Beheshtian A, Waubant E, Baranzini SE, Goodin DS et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology. 20093; 72: 800-805.
  • [8] Giorgio A, Stromillo ML, Rossi F, Battaglini M, Hakiki B, Portaccio E et al. Cortical lesions in radiologically isolated syndrome. Neurology. 2011; 77: 1896–1899.
  • [9] Ontaneda D, Fox RJ, Chataway J. Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. The Lancet Neurology. 2015; 14(2): 208-223.
  • [10] Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nature Reviews Neurology. 2012; 8: 647–656.
  • [11] Cross AH, Naismith RT (Washington University, St. Louis, MO, USA). Established and novel disease‐modifying treatments in multiple sclerosis. (Review). Journal of Internal Medicine. 2014; 275: 350–363.
  • [12] Mulero P, Midaglia L, Montalban X. Ocrelizumab: a new milestone in multiple sclerosis therapy. Therapeutic Advances in Neurological Disorders. 2018; 11: 1756286418773025.
  • [13] Storch MK, Piddlesden S, Haltia M, Iivanainen M, Morgan P, Lassmann H. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Annals of Neurology. 1998; 43: 465-71.
  • [14] Wolinsky JS, Montalban X, Hauser SL, Model F, Deol-Bhullar G, Garren H et al. Sustained and durable reduction in confirmed disability progression in patients with primary progressive multiple sclerosis receiving ocrelizumab: findings from the phase III ORATORIO study extended control period. P1234. ECTRIMS. Paris, France. Oct 27, 2017; 200889.
  • [15] Ocrevus: EPAR-Product Information. European Medicines Agency. 2017. URL: [13.04.2018].
  • [16] Subei AM, Cohen JA. Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis. CNS drugs. 2015; 29(7): 565-575.
  • [17] Gajofatto A. Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date. Drug Design, Development and Therapy. 2017; 11: 3153-3157.
  • [18] Marziniak M, Meuth S. Current Perspectives on Interferon Beta-1b for the Treatment of Multiple Sclerosis. Advances in Therapy. 2014; 31(9): 915-931.
  • [19] European Medicines Agency. Betaferon––European Public Assessment Report: summary for the public. May 2012.
  • [20] Reder AT, Ebers GC, Traboulsee A, Li D, Langdon D, Goodin DS et al. Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing–remitting MS. Neurology. 2010; 74: 1877–1885.
  • [21] Thakur K, Manuel L, Tomlinson M. Autoinjectors for administration of interferon beta-1b in multiple sclerosis: patient preferences and the ExtaviProTM 30G and Betacomfort® devices. Pragmatic and Observational Research. 2013; 4: 19-26.
  • [22] Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet. 1992; 340 (8825): 952–956.
  • [23] Alvarez‐Gonzalez C, Adams A, Mathews J, Turner BP, Giovannoni G, Baker D et al. Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis. Annals of Clinical and Translational Neurology. 2017; 4(7): 506-511.
  • [24] Holmoy T, Torkildsen O, Myhr KM. An update on cladribine for relapsing-remitting multiple sclerosis. Expert Opinion Pharmacotherapy 2017.
  • [25] Stankiewicz JM, Kolb H, Karni A, Weiner HL. Role of Immunosuppressive Therapy for the Treatment of Multiple Sclerosis. Neurotherapeutics. 2013; 10(1): 77-88.
  • [26] Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW. Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2010; 74: 1463–1670.
  • [27] Santana VM, Hurwitz CA, Blakley RL, Crom WR, Luo X, Roberts WM et al. Complete hematologic remissions induced by 2‐chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukaemia. Blood. 1994; 84: 1237–1242.
  • [28] Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M et al. Meningeal B‐cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007; 130(Pt 4): 1089–1104.
  • [29] Hafler DA, Orav J, Gertz R, Stazzone L, Weiner HL. Immunologic effects of cyclophosphamide/ACTH in patients with chronic progressive multiple sclerosis. Journal of Neuroimmunology. 1991; 32: 149 –158.
  • [30] Makhani N, Gorman MP, Branson HM, Stazzone L, Banwell BL, Chitnis T. Cyclophosphamide therapy in paediatric multiple sclerosis. Neurology. 2009; 72: 2076–2082.
  • [31] Neuhaus O, Kieseier BC, Hartung HP. Immunosuppressive agents in multiple sclerosis. Neurotherapeutics. 2007; 4: 654–660.
  • [32] Kalincik T, Horakova D, Dolezal O, Krásenský J, Vaněčková M, Seidl Z et al. Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort. Clinical Neurology and Neurosurgery. 2012; 114: 940–6. 59.
  • [33] Massacesi L, Tramacere I, Amoroso S, Battaglia MA, Benedetti MD, Filippini G et al. Azathioprine versus Beta Interferons for Relapsing-Remitting Multiple Sclerosis: A Multicentre Randomized Non-Inferiority Trial. Ruprecht K, ed. PLoS ONE. 2014; 9(11): e113371.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.